What is the share price of Balaxi Pharmaceuticals Ltd (BALAXI) today?
The share price of BALAXI as on 5th December 2025 is ₹34.12. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Balaxi Pharmaceuticals Ltd (BALAXI) share?
The past returns of Balaxi Pharmaceuticals Ltd (BALAXI) share are- Past 1 week: -11.59%
- Past 1 month: -21.69%
- Past 3 months: -24.80%
- Past 6 months: -31.40%
- Past 1 year: -57.70%
- Past 3 years: -69.91%
- Past 5 years: -73.04%
What are the peers or stocks similar to Balaxi Pharmaceuticals Ltd (BALAXI)?
The peers or stocks similar to Balaxi Pharmaceuticals Ltd (BALAXI) include:What is the market cap of Balaxi Pharmaceuticals Ltd (BALAXI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹193.06 Cr as of 5th December 2025.What is the 52 week high and low of Balaxi Pharmaceuticals Ltd (BALAXI) share?
The 52-week high of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹85.58 and the 52-week low is ₹34.What is the PE and PB ratio of Balaxi Pharmaceuticals Ltd (BALAXI) stock?
The P/E (price-to-earnings) ratio of Balaxi Pharmaceuticals Ltd (BALAXI) is 7.70. The P/B (price-to-book) ratio is 0.83.Which sector does Balaxi Pharmaceuticals Ltd (BALAXI) belong to?
Balaxi Pharmaceuticals Ltd (BALAXI) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.How to buy Balaxi Pharmaceuticals Ltd (BALAXI) shares?
You can directly buy Balaxi Pharmaceuticals Ltd (BALAXI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Balaxi Pharmaceuticals Ltd
BALAXI Share Price
34.122.43% (-0.85)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
BALAXI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
BALAXI Performance & Key Metrics
BALAXI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.30 | 0.83 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
BALAXI Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
BALAXI Company Profile
The company is engaged in wholesale trading of pharmaceuticals products, food products and builders’ hardware products. The Company offers a range of food and biscuit products under the brand name YAP.
PE Ratio
57.38
57.38
1Y Return
15.01%
15.01%
Buy Reco %
71.43
71.43
POLYMED
PE Ratio
57.21
57.21
1Y Return
33.55%
33.55%
Buy Reco %
66.67
66.67
FISCHER
PE Ratio
2,040.43
2,040.43
1Y Return
39.58%
39.58%
Buy Reco %
0.00
0.00
LAXMIDENTL
PE Ratio
47.65
47.65
1Y Return
49.96%
49.96%
Buy Reco %
100.00
100.00
TARSONS
PE Ratio
40.73
40.73
1Y Return
48.19%
48.19%
Buy Reco %
100.00
100.00
BALAXI Forecast
BALAXI Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
BALAXI
BALAXI
Income
Balance Sheet
Cash Flow
Annual Normal View
BALAXI Income Statement
BALAXI Income Statement
Annual Normal View
| Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 14.49 | 46.22 | 233.56 | 284.36 | 339.07 | 241.92 | 294.92 | 278.53 | ||||||||
Raw Materials | 0.00 | 32.83 | 172.15 | 195.60 | 202.42 | 128.68 | 165.70 | 254.61 | ||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.35 | 0.28 | 0.04 | 0.04 | |||||||||
| Employee Cost | 0.90 | 2.10 | 8.47 | 12.47 | 28.95 | 28.04 | 34.74 | |||||||||
| Selling & Administrative Expenses | 0.59 | 1.75 | 4.74 | 17.56 | 42.29 | 36.02 | 53.13 | |||||||||
| Operating & Other expenses | 10.55 | 0.70 | 3.30 | 2.59 | 5.08 | 42.27 | 6.74 | |||||||||
EBITDA | 2.45 | 8.84 | 44.90 | 55.79 | 60.05 | 6.87 | 34.57 | 23.92 | ||||||||
| Depreciation/Amortization | 0.00 | 0.01 | 0.30 | 0.51 | 1.75 | 2.10 | 1.89 | 1.88 | ||||||||
| PBIT | 2.45 | 8.83 | 44.60 | 55.28 | 58.30 | 4.77 | 32.68 | 22.04 | ||||||||
| Interest & Other Items | 0.00 | 0.05 | 0.28 | 0.76 | 1.38 | 2.77 | 4.01 | 4.02 | ||||||||
| PBT | 2.45 | 8.78 | 44.32 | 54.52 | 56.92 | 2.00 | 28.67 | 18.02 | ||||||||
| Taxes & Other Items | 0.47 | 2.69 | 6.19 | 6.86 | 10.96 | 4.40 | 3.60 | 3.50 | ||||||||
| Net Income | 1.98 | 6.09 | 38.13 | 47.66 | 45.96 | -2.40 | 25.07 | 14.52 | ||||||||
| EPS | 1.30 | 1.87 | 7.63 | 9.53 | 9.11 | -0.15 | 1.53 | 2.63 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
BALAXI Company Updates
FY 2026FY 2026
Investor Presentation
Nov 14PDF
Aug 8PDF
FY 2025FY 2025
Investor Presentation
Jun 7PDF
Feb 13PDF
Nov 13PDF
FY 2024FY 2024
Investor Presentation
Aug 3PDF
FY 2023FY 2023
Investor Presentation
May 29PDF
Feb 1PDF
Nov 5PDF
Aug 2PDF
BALAXI Stock Peers
BALAXI Past Performance & Peer Comparison
BALAXI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHealth Care Equipment & Supplies
Compare valuation on Screener
Health CareHealth Care Equipment & Supplies
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Balaxi Pharmaceuticals Ltd | 7.70 | 0.83 | — |
| Inventurus Knowledge Solutions Ltd | 57.38 | 15.58 | — |
| Poly Medicure Ltd | 57.21 | 7.00 | 0.18% |
| Fischer Medical Ventures Ltd | 2,040.43 | 9.00 | 0.10% |
BALAXI Stock Price Comparison
Compare BALAXI with any stock or ETFCompare BALAXI with any stock or ETF
BALAXI
BALAXI Holdings
BALAXI Shareholdings
BALAXI Promoter Holdings Trend
BALAXI Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
BALAXI Institutional Holdings Trend
BALAXI Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.22%
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 5.37%
BALAXI Shareholding Pattern
BALAXI Shareholding Pattern
BALAXI Shareholding History
BALAXI Shareholding History
Foreign Institutions
smallcases containing BALAXI stock
smallcases containing BALAXI stock
Looks like this stock is not in any smallcase yet.
BALAXI Events
BALAXI Events
BALAXI Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
BALAXI Dividend Trend
No dividend trend available
BALAXI Upcoming Dividends
BALAXI Upcoming Dividends
No upcoming dividends are available
BALAXI Past Dividends
BALAXI Past Dividends
Cash Dividend
Ex DateEx DateJul 1, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jul 1, 2022
BALAXI Stock News & Opinions
BALAXI Stock News & Opinions
Articles & Videos
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 95.42% in the September 2025 quarter
Net profit of Balaxi Pharmaceuticals declined 95.42% to Rs 0.21 crore in the quarter ended September 2025 as against Rs 4.59 crore during the previous quarter ended September 2024. Sales declined 27.40% to Rs 56.18 crore in the quarter ended September 2025 as against Rs 77.38 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales56.1877.38 -27 OPM %2.0613.69 - PBDT1.866.03 -69 PBT1.385.56 -75 NP0.214.59 -95 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to announce Quarterly Result
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 95.52% in the June 2025 quarter
Net profit of Balaxi Pharmaceuticals declined 95.52% to Rs 0.29 crore in the quarter ended June 2025 as against Rs 6.48 crore during the previous quarter ended June 2024. Sales rose 7.80% to Rs 70.74 crore in the quarter ended June 2025 as against Rs 65.62 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales70.7465.62 8 OPM %5.8715.38 - PBDT1.377.87 -83 PBT0.907.37 -88 NP0.296.48 -96 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to announce Quarterly Result
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals AGM scheduled
Balaxi Pharmaceuticals announced that the 82th Annual General Meeting(AGM) of the company will be held on 25 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 20.95% in the March 2025 quarter
Net profit of Balaxi Pharmaceuticals declined 20.95% to Rs 8.64 crore in the quarter ended March 2025 as against Rs 10.93 crore during the previous quarter ended March 2024. Sales rose 27.48% to Rs 76.27 crore in the quarter ended March 2025 as against Rs 59.83 crore during the previous quarter ended March 2024. For the full year,net profit declined 30.19% to Rs 25.07 crore in the year ended March 2025 as against Rs 35.91 crore during the previous year ended March 2024. Sales rose 21.25% to Rs 292.56 crore in the year ended March 2025 as against Rs 241.29 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales76.2759.83 27 292.56241.29 21 OPM %16.4522.51 -12.7219.37 - PBDT10.1211.07 -9 30.5642.41 -28 PBT9.6610.40 -7 28.6740.31 -29 NP8.6410.93 -21 25.0735.91 -30 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to convene board meeting
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 60.56% in the December 2024 quarter
Net profit of Balaxi Pharmaceuticals declined 60.56% to Rs 5.36 crore in the quarter ended December 2024 as against Rs 13.59 crore during the previous quarter ended December 2023. Sales rose 20.56% to Rs 73.29 crore in the quarter ended December 2024 as against Rs 60.79 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales73.2960.79 21 OPM %5.4422.47 - PBDT6.5513.11 -50 PBT6.0712.63 -52 NP5.3613.59 -61 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to convene board meeting
Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 68.19% in the September 2024 quarter
Net profit of Balaxi Pharmaceuticals declined 68.19% to Rs 4.59 crore in the quarter ended September 2024 as against Rs 14.43 crore during the previous quarter ended September 2023. Sales rose 41.41% to Rs 77.38 crore in the quarter ended September 2024 as against Rs 54.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales77.3854.72 41 OPM %13.6919.66 - PBDT6.0310.67 -43 PBT5.5610.01 -44 NP4.5914.43 -68 Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 44.87%, vs industry avg of 24.67%
Over the last 5 years, market share increased from 2.21% to 3.95%
Over the last 5 years, net income has grown at a yearly rate of 32.71%, vs industry avg of 28.7%